Indegene Limited achieved historic financial milestones in FY26, with quarterly revenue exceeding ₹1,000 crores for the first time and annual revenue surpassing ₹3,500 crores. The company reported 23.6% growth in INR terms and 18.2% in dollar terms. Driven by GenAI-led innovation and strategic acquisitions, Indegene continues to expand its global customer base and deepen relationships with top-tier life sciences organizations, setting a positive outlook for FY27.
Record-Breaking Financial Performance
Indegene Limited reported a strong financial year ending March 31, 2026. The company marked a significant milestone in Q4 FY26, with revenues crossing the ₹1,000 crore threshold, contributing to a full-year revenue of ₹35,105 million. This performance represents a robust growth of 23.6% year-on-year in INR terms. The company also maintained strong cash generation, with operating cash flows reaching ₹6,508 million, a 162% ratio on profit after tax.
Strategic Growth and GenAI Integration
Innovation remains at the core of Indegene’s operations. The company has successfully scaled its GenAI-led solutions, which are now being integrated into medical and regulatory domains. A key highlight for the year was the Tectonic transformation model, which aims to disrupt traditional agency cycles, reducing project timelines from months to days. Indegene has secured 5 customers for this model, with several transitioning into long-term strategic engagements.
Market Expansion and Customer Relationships
Indegene’s diversified portfolio continues to scale, with the active customer base growing from 73 to 91 during the year. Notably, the number of customers contributing over $1 million in annual revenue increased by 30%, reaching 53. The company has made strategic acquisitions, including BioPharm, Warn, and Cake Communications, to strengthen its omnichannel capabilities and local market presence in Europe and North America.
Outlook for FY27
Looking ahead, the company is entering FY27 with high confidence. With a larger, more qualified pipeline and a focus on scaling GenAI-driven platforms, Indegene expects to continue delivering sustainable growth. Management anticipates that investments made in the previous year will be fully absorbed, driving margin improvements and consistent revenue expansion in the latter half of FY27. The Board has proposed a final dividend of ₹2.25 per equity share, reflecting confidence in the company’s long-term financial health.
Source: BSE
